Companies · Listed company · 🇮🇳

Biocon Limited

BIOCON · NSE · ₹371 a share (close of 01 Oct 2026)

Available company data, source links and archived checks for Biocon Limited. Read each source and date: a past check is not a fresh review, and some earlier figures have incomplete source details.

Revenue rose 10.0%; Net profit was ₹136.80 crore.

Quarter ended 2026-06-30 · consolidated · Company filing

Recorded quarterly figures

Quarter	Revenue / income	YoY	Profit	YoY	Net margin	Source
Jun 2026	Revenue: ₹4,336 cr	+10.0%	Net profit: ₹137 cr	+53.4%	3.2%	Company filing source
Mar 2026	Revenue: ₹4,517 cr	+2.3%	Net profit: ₹199 cr	-56.8%	4.4%	Company filing source
Dec 2025	Revenue: ₹4,173 cr	—	Net profit: ₹-52 cr	—	-1.2%	Company filing source
Sep 2025	Revenue: ₹4,296 cr	—	Net profit: ₹133 cr	—	3.1%	Company filing source
Jun 2025	Revenue: ₹3,942 cr	+14.8%	Net profit: ₹89 cr	-89.6%	2.3%	Company filing source
Mar 2025	Revenue: ₹4,417 cr	—	Net profit: ₹459 cr	—	10.4%	Company filing source

YoY means change from the same quarter a year earlier. — means no comparable figure is available. Older entries with incomplete source details have not been revalidated under the current checks.

Recently checked facts

BIOCON: consolidated net profit changed by 53.4% in the quarter ending 30 June 2026, compared with the quarter ending 2025-06-30.

✓ verified by recomputing archived check · 2026-09-22 exchange filing →

BIOCON: consolidated net profit for the quarter ending 30 June 2026 was ₹136.80 crore.

✓ verified by recomputing archived check · 2026-09-22 exchange filing →

BIOCON: consolidated revenue changed by 10.0% in the quarter ending 30 June 2026, compared with the quarter ending 2025-06-30.

✓ verified by recomputing archived check · 2026-09-22 exchange filing →

BIOCON: consolidated revenue for the quarter ending 30 June 2026 was ₹4,336.00 crore.

✓ verified by recomputing archived check · 2026-09-22 exchange filing →

Who holds it — from the filings

KIRAN MAZUMDAR SHAW 29.7%GLENTEC INTERNATIONAL 14.6%MAGNUM HYBRID LONG SHORT FUND 8.8%MYLAN INC. 5.6%LIFE INSURANCE CORPORATION OF INDIA 3.7%register as filed 2026-06-30

Filing timeline — what the company told the exchange

Options to purchase securities. Biocon Limited has informed the Exchange about Grant of Employee Stock Options under Biocon Unity Long Term Incentive Plan 2026 … 01 Oct 2026 · document
Biocon Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015… 30 Sep 2026 · document
Updates. Biocon Limited has informed the Exchange regarding 'Company Statement'.… 25 Sep 2026 · document
Press Release. Biocon Limited has informed the Exchange regarding a press release dated September 21, 2026, titled "Biocon s Pertuzumab Becomes First Biosimilar… 21 Sep 2026 · document
General Updates. Biocon Limited has informed the Exchange about Communication regarding remittance of final dividend for the FY 2025-26… 09 Sep 2026 · document
Analysts/Institutional Investor Meet/Con. Call Updates. Biocon Limited has informed the Exchange about Schedule of meet… 08 Sep 2026 · document
Press Release. Biocon Limited has informed the Exchange regarding a press release dated September 08, 2026, titled "Biocon Secures 10-Year Supply Contract for P… 08 Sep 2026 · document
Analysts/Institutional Investor Meet/Con. Call Updates. Biocon Limited has informed the Exchange about Schedule of meet… 31 Aug 2026 · document

Follow this company without reading every document yourself.

Keep its available filings, dated fact checks and disclosure alerts together. Your saved country sets your market and its research schedule.

Start free — first week on us →

India ₹149/month · Rest of world US$4.99/month after the free trial · research, not investment advice · cancel any time

Company data and archived claim checks are shown with available sources. Check the source and date before relying on a figure. This is not investment advice or a recommendation. Investment in securities markets is subject to market risks. Research on this site is produced with substantial use of AI. Terms, disclosures and grievances